- Catalog number
- ICH1132-50mg
- Size / count
- 50 mg
- Dry ice
- No
- Hazardous
- No
- Discontinued
- No
- Background
- CD279, also known as programmed death-1 (PD-1) is a 50-55 kD immunoglobulin superfamily member. PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells. The PD-1 ligands, PD-L1 (also known as B7-H1) and PD-L2 (B7-DC), are members of the B7 immunoglobulin superfamily. This RMP1-14 antibody has been reported to block the binding of PD-1 to its ligands (B7-H1 and B7-DC) and to inhibit T cell proliferation and cytokine production.
- CAS Number
- 9007-83-4
- Specifications
- Anti-PD-1 In Vivo Antibody - Low Endotoxin (RMP1-14) recognizes an epitope on Mouse PD-1
- Product Name Alternative
- Programmed cell death protein 1, Pdcd1, CD279
- UniProt
- Q02242
- Host
- Rat
- Species Reactivity
- Mouse
- Target
- PD-1
- Isotype
- IgG2a Kappa
- Clone
- RMP1-14
- Applications
- Western Blot, Blocking, Flow Cytometry, Functional Assays
- Purification Method
- This monoclonal antibody was purified using Protein G
- Concentration
- 1.0 - 5.0 mg/mL
- Endotoxin
- ≤ 1.0 EU/mg as determined by the LAL method
- Purity
- >95% by SDS-PAGE and HPLC
- Buffer
- ICH3001-100mL
ICH3002-100mL
ICH3003-100mL
- Shipping Conditions
- Blue ice
- Storage Conditions
- Anti-PD-1 In Vivo Antibody - Low Endotoxin (RMP1-14) is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -70oC.
- Formulation
- 0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.
- Antigen Distribution
- Subset of double negative thymocytes, activated T and B cells
- Aggregation
- Aggregation level ≤ 5%
- Applications Notes
- Blocking: Clone RMP1-14 antibody has been shown to block the binding of both mouse PD-L1-Ig and mouse PD-L2-Ig to PD-1. For immune checkpoint antibodies 200 ug per mouse per injection is the standard dosage in the literature. For this anti-PD-1 (clone RMP1-14), we suggest to inject 200 ug/mouse ip generally on days 3, 6 and 9, post injection of tumor. Sometime up to six injections depending on the length of the experiment may be required.
Each investigator should determine their own optimal working dilution for specific applications.
- Isotype Control
- https://www.ichor.bio/product/Rat-IgG2a-In-Vivo-Isotype-Control-Low-Endotoxin-1-1-ICH2244